Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Eli Lilly to acquire Phase 1/2 DICE Thera for US$2.4 Billion

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Jul 25, 2023 3:07pm

114 Views

Post# 35556440

RE:RE:RE:RE:RE:RE:Eli Lilly to acquire Phase 1/2 DICE Thera for US$2.4 Billion

Dear jmsenior. Maybe you should have read the post that prompted my response. Or perhaps your criticism is selective, for obvious reasons. On the other hand, I don't care what you think.

<< Previous

Bullboard Posts

Next >>

Advancing flagship Ishkõday Gold Project in Ontario